Alkem Laboratories Ltd. reported robust performance for the second quarter ended 30 September 2025. The company recorded revenues of Rs. 40,010 million, up by 17.2 % year-on-year. EBITDA rose 22.3 % to Rs. 9,208 million — yielding a margin of 23.0 % versus 22.0 % a year ago.
Domestic sales reached Rs. 27,660 million, growing 12.4 % YoY, and contributing nearly 69.9 % of total revenue. International operations surged, with revenues of Rs. 11,890 million — up 29.5 % YoY. Of this, U.S. sales stood at Rs. 7,649 million (- grew 28.0 % YoY) and non-U.S. international sales at Rs. 4,241 million (+32.4 % YoY).
Alkem out-performed the broader Indian Pharmaceutical Market (IPM) in six key therapy segments including gastrointestinal, VMN (vitamins/minerals/nutrients), pain, respiratory and derma. R&D spend declined to Rs. 1,302 million in Q2 (3.3 % of revenue) compared with Rs. 1,465 million (4.3 %) in the previous year.
In the U.S. market, the company filed 2 ANDAs, received 1 tentative ANDA approval and launched 4 products in the quarter. As of 30 Sep 2025, Alkem has filed 187 ANDAs, 2 NDAs and 1 BLA; approvals secured stand at 163 ANDAs (including 17 tentative) and 2 NDAs.
Dr. Vikas Gupta, CEO of Alkem, said: “Q2 FY26 has been another strong quarter for us, marked by robust growth across India, the US, and key international markets. We also saw healthy traction in new product launches across markets. Our improved gross margins and operating leverage have contributed to a stronger EBITDA profile. As we look ahead, we remain focused on accelerating growth and continue to strengthen our presence in key markets.”
